1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 39 pages

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Five Prime Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Five Prime Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Five Prime Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Five Prime Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Five Prime Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Five Prime Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Five Prime Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Five Prime Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Five Prime Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Five Prime Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Five Prime Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Five Prime Therapeutics, Inc. Snapshot 5
Five Prime Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Five Prime Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Five Prime Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Five Prime Therapeutics, Inc. - Pipeline Products Glance 14
Five Prime Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Five Prime Therapeutics, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Five Prime Therapeutics, Inc. - Drug Profiles 17
FPA-008 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
FP-1039 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
FPA-144 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
INBRX-110 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Monoclonal Antibodies for Cancer 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Monoclonal Antibodies for Solid Tumors 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Proteins for Asthma and Chronic Obstructive Pulmonary Disease 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Proteins for Central Nervous System Disorders 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Five Prime Therapeutics, Inc. - Pipeline Analysis 28
Five Prime Therapeutics, Inc. - Pipeline Products by Target 28
Five Prime Therapeutics, Inc. - Pipeline Products by Route of Administration 29
Five Prime Therapeutics, Inc. - Pipeline Products by Molecule Type 30
Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action 31
Five Prime Therapeutics, Inc. - Recent Pipeline Updates 32
Five Prime Therapeutics, Inc. - Dormant Projects 36
Five Prime Therapeutics, Inc. - Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Five Prime Therapeutics, Inc., Key Information 5
Five Prime Therapeutics, Inc., Key Facts 5
Five Prime Therapeutics, Inc. - Pipeline by Indication, 2015 7
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015 10
Five Prime Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Five Prime Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015 12
Five Prime Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Five Prime Therapeutics, Inc. - Phase I, 2015 14
Five Prime Therapeutics, Inc. - Preclinical, 2015 15
Five Prime Therapeutics, Inc. - Discovery, 2015 16
Five Prime Therapeutics, Inc. - Pipeline by Target, 2015 28
Five Prime Therapeutics, Inc. - Pipeline by Route of Administration, 2015 29
Five Prime Therapeutics, Inc. - Pipeline by Molecule Type, 2015 30
Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 31
Five Prime Therapeutics, Inc. - Recent Pipeline Updates, 2015 32
Five Prime Therapeutics, Inc. - Dormant Developmental Projects,2015 36

List of Figures
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 7
Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015 10
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 28
Five Prime Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 30
Five Prime Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.